Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
- 9 July 2012
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (1) , 83-89
Abstract
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003 and June 2006, in whom treatment cost was reimbursed under the Civil Servant Medical Benefit Scheme (CSMBS) (n =201) or the Universal Coverage Scheme (UCS) (n =352). The international prognostic index was comparable between the two payment groups. Rituximab-based therapy was administered in 45.3% and 3.1% of CSMBS and UCS patients, respectively (p p =0.005). “Not treated with rituximab-based therapy” was the strongest adverse prognostic feature indicating a short PFS (hazard ratio 2.1, p <0.001). It is concluded that lack of access to rituximab is the principal factor accounting for the inferior PFS observed in Thai patients with DLBCL who are treated under the UCS.Keywords
This publication has 16 references indexed in Scilit:
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2011
- Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER DataClinical Lymphoma Myeloma and Leukemia, 2011
- Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathyLeukemia & Lymphoma, 2009
- Universal Coverage In The Land Of Smiles: Lessons From Thailand’s 30 Baht Health ReformsHealth Affairs, 2007
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958